v3.26.1
Stockholders' Equity (Tables)
6 Months Ended
Jun. 30, 2026
Stockholders' Equity [Abstract]  
Schedule of Outstanding Warrants to Purchase Common Stock Issued to Stockholders

As of June 30, 2026, the Company had the following outstanding warrants to purchase Common Stock issued to stockholders:

 

Warrant   Issuance
Date
  Expiration
Date
  Exercise Price Per Share     Number of Shares of Common Stock Underlying Warrants  
                     
2021 Registered Direct Offering Warrants   July 28, 2021   January 28, 2027     950.00       14,808  
Merger Warrants   March 15, 2024   January 28, 2027     950.00       11,404  
Private Placement Warrants   March 15, 2024   July 9, 2026     43.91       203,444  
Registered Pre-Funded Warrants   February 25, 2025   April 21, 2030     0.0019       42,381  
Private Pre-Funded Warrants   February 25, 2025   April 21, 2030     0.0019       46,232  
Common Warrants   February 25, 2025   April 21, 2030     17.68       312,503  
Inducement Warrants   February 25, 2025   April 21, 2030     17.68       366,087  
A&R Warrants   February 25, 2025   April 21, 2030     0.0019       25,119  
                      1,021,978  

As of June 30, 2026, the Company had the following outstanding compensation related warrants to purchase Common Stock:

 

Warrant   Issuance
Date
  Expiration
Date
  Exercise Price Per Share     Number of Shares of Common Stock Underlying Warrants  
                     
Private Warrants issued to scientific founders*   November 27, 2017   -     -       16  
Landlord Warrants   March 15, 2024   January 28, 2027     950.00       1,316  
Agents Warrants   March 15, 2024   July 9, 2026     43.91       50,126  
January 2026 private placement  agent warrants   January 13, 2026   January 12, 2031     2.50       99,000  
                      150,458  

 

* In November 2017, BiomX Israel issued 298 warrants to its founders. The warrants were fully vested at their grant date and will expire immediately prior to a consummation of an M&A transaction. The warrants did not expire as a result of the Recapitalization Transaction and have no exercise price.
Schedule of Options Granted to Purchase the Company’s Common Stock Under the Company’s Share Option Plans

A summary of options granted to purchase the Company’s Common Stock under the Company’s share option plans is as follows:

 

    For the Six Months Ended June 30, 2026  
    Number of Options     Weighted Average Exercise Price     Aggregate Intrinsic Value  
Outstanding at the beginning of period     150,387     $ 51.94     $ -  
Granted     -       -              -  
Forfeited     148,675       36.68       -  
Expired     1,712       32.53       -  
Exercised     -       -       -  
Outstanding at the end of period     -       -     $ -  
Exercisable at end of period     -       -          
Weighted average remaining contractual life – years as of June 30, 2026     -                  
Schedule of Stock-Based Payment Expenses

The following table sets forth the total stock-based payment expenses resulting from options, RSUs and warrants granted, included in the consolidated statements of operations:

 

    Three Months Ended June 30,     Six Months Ended June 30,  
    2026     2025     2026     2025  
                         
Research and development expenses, net     -       279       (647 )     467  
General and administrative     3,988       417       2,707       888  
      3,988       696       2,060       1,355